Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States

IntroductionNovel therapies for 3L+ relapsed/refractory (r/r) follicular lymphoma (FL) have been approved recently by the US Food and Drug Administration including anti-CD19 CAR-T therapies such as axicabtagene ciloleucel (axi-cel) and CD20 × CD3 T-cell-engaging bispecific monoclonal antibodies such...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Frontiers in Immunology
المؤلفون الرئيسيون:	Olalekan O. Oluwole, Markqayne D. Ray, Richard M. Zur, Cheryl P. Ferrufino, Brett Doble, Anik R. Patel, S. Pinar Bilir
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2024-05-01
الموضوعات:	axicabtagene ciloleucel mosunetuzumab cost-effectiveness analysis relapsed or refractory follicular lymphoma indolent non-Hodgkin lymphoma
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1393939/full